Home / Renal Diseases (page 3)

Renal Diseases

Arrowhead Pharma Halts Work on Lead Hepatitis B Drugs, Focuses on Subcutaneous and Extra-Hepatic RNAi Therapeutics

PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the company’s new proprietary subcutaneous (subQ) and extra-hepatic delivery systems. Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv™, …

Read More »

Alexion Announces that Data from Global aHUS Registry Shows Reduced Risk with Soliris

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an analysis of patients enrolled in the Global atypical Hemolytic Uremic Syndrome (aHUS) Registry, demonstrating that initiation of Soliris® (eculizumab) prior to kidney transplant reduces the risk of dialysis post-transplant in patients with aHUS. Specifically, …

Read More »

Exelixis’ Kidney Cancer Drug Beats Pfizer’s Sutent in Mid-Stage Study

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Oct. 10, 2016– Exelixis, Inc.(NASDAQ:EXEL) today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Principal investigator Toni …

Read More »

FDA Approves OPKO Health’s Rayaldee for CKD-Related Secondary Hyperparathyroidism

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) announced that the U.S. Food and Drug Administration (FDA) has approved RAYALDEE®(calcifediol) extended release capsules for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. RAYALDEE …

Read More »

Gilead Acquires Nimbus’ NASH Drug in $1.28 Billion Deal

FOSTER CITY, Calif. & CAMBRIDGE, Mass., April 4, 2016—Gilead Sciences, Inc. (NASDAQ: GILD) and Nimbus Therapeutics, LLC today announced that the companies have signed a definitive agreement under which Gilead will acquire Nimbus Apollo, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and its Acetyl-CoA Carboxylase (ACC) inhibitor program. Nimbus Therapeutics …

Read More »

FDA Approves Jazz Pharmaceuticals’ Rare Liver Disease Drug

DUBLIN, March 30, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted marketing approval for Defitelio® (defibrotide sodium) for the treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary …

Read More »

AstraZeneca Announces Positive Late-Stage Results for the Treatment of Hyperuricemia Associated with Gout

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced positive subanalysis data of the Phase III lesinurad studies (CLEAR1, CLEAR2 and CRYSTAL) for the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor (XOI).The results demonstrated a consistent efficacy and safety profile in patients with normal renal function, as well …

Read More »

Shire’s Cinryze Receives Fast Track Status from the FDA for AMR in Kidney Transplant Patients

Lexington, MA – October 13, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of CINRYZE® (C1 esterase inhibitor [human]) for intravenous administration in subjects with Antibody Mediated Rejection (AMR) in renal …

Read More »

FDA Grants Fast Track Status to Exelixis’ Kidney Cancer Drug

The US Food and Drug Administration (FDA) has granted Fast Track designation to Exelixis’ renal cell carcinoma (RCC) drug. The agency provided fast track status for Exelixis’ investigational cabozantinib for the treatment of patients with advanced RCC who have received one prior therapy. The news sent the company’s shares up …

Read More »

Hospira Presents Data Demonstrating the Biosimilarity Between Amgen’s Epogen and Hospira’s Proposed Biosimilar

Hospira, Inc. presented two studies supporting biosimilar application for Epoetin Hospira in the US. Hospira, a global leader in biosimilars and the world’s leading provider of injectable drugs and infusion technologies, presented two studies at the National Kidney Foundation (NKF) Spring Meeting. The two presentations were “PK/PD Equivalence of Epoetin …

Read More »